Table II. Classification of AD and nondemented controls. Compare AUC calculated using variables selected in elastic net models (Table I) with AUC calculated using established markers for pathology. See also ROC curves in Figures 2 and 3.
| Established biomarker model | CSF sample set (n = 43) |
||
|---|---|---|---|
| AUC calculated based on established biomarkers in CSFa | E-net model | AUC calculated based on CSF communicome, age, and APOE4 statusb | |
| t-tau | 0.86 (0.71–0.94) | C1 | 0.75 (0.56–0.88) |
| p-tau181 | 0.90 (0.74–0.97) | C2 | 0.88 (0.70–0.96) |
| Aβ1–42 | 0.75 (0.58–0.87) | C3 | n.a. |
| Aβ1–42/t-tau | 0.84 (0.69–0.93) | C4 | 0.91 (0.77–0.97) |
| Aβ1–42/p-tau181 | 0.86 (0.70–0.94) | C5 | 0.93 (0.78–0.98) |
| Established biomarker model | Training set (n = 131) |
||
|---|---|---|---|
| AUC calculated based on established biomarkers in CSFa | E-net model | AUC calculated based on plasma communicome, age, and APOE4 statusb | |
| t-tau | 0.80 (0.71–0.87) | P6 | 0.86 (0.79–0.92) |
| p-tau181 | 0.82 (0.73–0.89) | P7 | 0.86 (0.78–0.92) |
| Aβ1–42 | 0.81 (0.72–0.87) | P8 | 0.85 (0.76–0.90) |
| Aβ1–42/t-tau | 0.85 (0.78–0.91) | P9 | 0.86 (0.78–0.92) |
| Aβ1–42/p-tau181 | 0.84 (0.76–0.90) | P10 | 0.84 (0.76–0.90) |
| Established biomarker model | Test set (n = 65) |
||
|---|---|---|---|
| AUC calculated based on established biomarkers in CSFc | Validation of variables selected in E-net model | AUC calculated based on plasma communicome, age, and APOE4 status selected in the training setd | |
| t-tau | 0.80 (0.630–0.907) | P6 | 0.77 (0.63–0.87) |
| p-tau181 | 0.81 (0.648–0.909) | P7 | 0.76 (0.61–0.86) |
| Aβ1–42 | 0.84 (0.704–0.925) | P8 | 0.75 (0.60–0.85) |
| Aβ1–42/t-tau | 0.86 (0.715–0.938) | P9 | 0.77 (0.63–0.87) |
| Aβ1–42/p-tau181 | 0.86 (0.725–0.934) | P10 | 0.74 (0.60–0.85) |
a AUC calculated based on the levels of established pathological CSF biomarkers t-tau, p-tau181, Aβ1–42 and their ratios in subjects used for CSF or plasma models, respectively.
b AUC (in bold) calculated based on communicome, age and APOE4 status and their corresponding regression coefficients as selected in Elastic net (E-net) models C1–5 (CSF) and P6–10 (plasma) in subjects used for CSF or plasma models, respectively. Note that for Aβ1–42 only IL-7 with a regression coefficient close to 0 was selected in the E-net model C3. Thus, no ROC/AUC could be calculated (n.a., not applicable).
c These AUC results are based on 53 subjects because 6 controls and 6 AD patients had no measurement of Aβ and tau in CSF.
d Variables selected by the E-net models P6–10 in the training set were validated in an independent test set and AUC was calculated for all 65 subjects (italicized and bold).